CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News CytoDyn is actually  a   biotech that has been effective hard but unsuccessfully to create an one-time therapy, variously named Pro 140, leronlimab, and Vyrologix. In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terms of prospective indications. […]

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has been effective hard but unsuccessfully to create an one-time therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terms of prospective indications.

CytoDyn's inventories of leronlimab are actually building up, whether they'll actually be being used is actually an open question.


While CYDY  has been dawdling, promote opportunities for leronlimab as a combination treatment in the treatment of multi-drug-resistant HIV are actually closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of the past several shares of mine. The first CytoDyn post of mine, "CytoDyn: What to be able to Do When It's Too Good to be able to Be True?", set away all of the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such a very marketing picture in the Uptick Newswire employment interview that I came away with a poor impression of the company.

Irony of irony, the bad viewpoint of mine of the business has grown steadily, although the disappointment hasn't been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger at the moment still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much-storied therapy (which I shall relate to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc.... has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the therapy as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity in HIV- infected subjects. Today's transaction of $3.5 zillion transfers ownership of the expertise and associated intellectual property coming from Progenics to CytoDyn, and approximately twenty five million mg of bulk drug substance.... milestone payments after commencement of a level III clinical trial ($1.5 zillion) and also the very first new drug program endorsement ($five million), and also royalty payments of five percent of net sales upon commercialization.

Since that point in time, CytoDyn's guiding nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to get a sector cap > $3.5 billion. It's done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and many indications, it has this individual therapies and a "broad pipeline of indications" because it places it. I call such pipelines, "pipedots." In CytoDyn's case it touts the leronlimab of its as a potentially beneficial therapy in dozens of indications.

The opening banner of its on its website (below) shows an active company with diverse interests albeit focused on leronlimab, several illness sorts, multiple presentations and multiple publications.

Might all of it be smoke and mirrors? That is a question I have been asking myself with the very start of the interest of mine in this particular organization. Judging by way of the multiples of thousands of several remarks on listings accessible via Seeking Alpha's CytoDyn Summary page, I am much from alone in this question.

CytoDyn is a traditional battleground, or some may say cult inventory. Its adherents are fiercely protective of its prospects, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *